DK2731967T3 - Humane bindingsmolekyler, der er i stand til at neutralisere influenza a-virus fra fylogenetisk gruppe 1 og fylogenetisk gruppe 2 og influenza b-virus - Google Patents

Humane bindingsmolekyler, der er i stand til at neutralisere influenza a-virus fra fylogenetisk gruppe 1 og fylogenetisk gruppe 2 og influenza b-virus Download PDF

Info

Publication number
DK2731967T3
DK2731967T3 DK12735516.2T DK12735516T DK2731967T3 DK 2731967 T3 DK2731967 T3 DK 2731967T3 DK 12735516 T DK12735516 T DK 12735516T DK 2731967 T3 DK2731967 T3 DK 2731967T3
Authority
DK
Denmark
Prior art keywords
seq
influenza
binding
region
heavy chain
Prior art date
Application number
DK12735516.2T
Other languages
English (en)
Inventor
Theodorus Hendrikus Jacobus Kwaks
David A T M Zuijdgeest
Ronald Vogels
Robert Heinz Edward Friesen
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Application granted granted Critical
Publication of DK2731967T3 publication Critical patent/DK2731967T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Claims (7)

1. Isoleret antistof eller antigenbindende fragment deraf, der er i stand til at binde specifikt til en epitop i stilkregionen af hæmagglutininproteinet (HA) fra influenza A-virusundertyper af fylogenetisk gruppe 1 og influenza A-virusundertyper af fylogenetisk gruppe 2-undertyper og er i stand til at neutralisere mindst en eller flere gruppe 1- influenza A-virusundertyper udvalgt fra gruppen, der består af influenza A-virus, der omfatter HA af Hl-, H2-, H5-, H6-, H8-, H9- og Hl1-undertypen, og mindst en eller flere gruppe 2- influenza A-virusundertyper udvalgt fra gruppen, der består af influenza A-virus, der omfatter HA af H3-, H4-, H7- og H10- undertypen, der er kendetegnet ved, at antistoffet eller det antigenbindende fragment deraf også er i stand til at binde specifikt til hæmagglutininproteinet (HA) fra influenza B-virusundertyper.
2. Antistof eller antigenbindende fragment deraf ifølge krav 1, hvor antistoffet eller det antigenbindende fragment deraf ikke har nogen hæmagglutinationshæmmende aktivitet.
3. Antistof eller antigenbindende fragment deraf ifølge et hvilket som helst af ovennævnte krav, hvor antistoffet eller det antigenbindende fragment deraf er udvalgt fra gruppen, der består af: et antistof eller et antigenbindende fragment deraf, der omfatter en tung kædes CDRl-region ifølge SEQ ID NO: 139, en tung kædes CDR2-region ifølge SEQ ID NO: 134 og en tung kædes CDR3-region ifølge SEQ ID NO: 145 og en let kædes CDRl-region ifølge SEQ ID NO: 146, en let kædes CDR2-region ifølge SEQ ID NO: 174 og en let kædes CDR3-region ifølge SEQ ID NO: 147, en tung kædes CDRl-region ifølge SEQ ID NO: 139, en tung kædes CDR2-region ifølge SEQ ID NO: 134 og en tung kædes CDR3-region ifølge SEQ ID NO: 145 og en let kædes CDRl-region ifølge SEQ ID NO: 148, en let kædes CDR2-region ifølge SEQ ID NO: 149 og en let kædes CDR3-region ifølge SEQ ID NO: 150, en tung kædes CDRl-region ifølge SEQ ID NO: 139, en tung kædes CDR2-region ifølge SEQ ID NO: 134 og en tung kædes CDR3-region ifølge SEQ ID NO: 145 og en let kædes CDRl-region ifølge SEQ ID NO: 142, en let kædes CDR2-region ifølge SEQ ID NO: 143 og en let kædes CDR3-region ifølge SEQ ID NO: 173; et antistof eller et antigenbindende fragment deraf, der omfatter en tung kædes CDRl-region ifølge SEQ ID NO: 139, en tung kædes CDR2-region ifølge SEQ ID NO: 134 og en tung kædes CDR3-region ifølge SEQ ID NO: 152 og en let kædes CDRl-region ifølge SEQ ID NO: 148, en let kædes CDR2-region ifølge SEQ ID NO: 149 og en let kædes CDR3-region ifølge SEQ ID NO: 150, en tung kædes CDRl-region ifølge SEQ ID NO: 139, en tung kædes CDR2-region ifølge SEQ ID NO: 134 og en tung kædes CDR3-region ifølge SEQ ID NO: 152 og en let kædes CDRl-region ifølge SEQ ID NO: 156, en let kædes CDR2-region ifølge SEQ ID NO: 157 og en let kædes CDR3-region ifølge SEQ ID NO: 158, en tung kædes CDRl-region ifølge SEQ ID NO: 139, en tung kædes CDR2-region ifølge SEQ ID NO: 130 og en tung kædes CDR3-region ifølge SEQ ID NO: 152 og en let kædes CDRl-region ifølge SEQ ID NO: 171, en let kædes CDR2-region ifølge SEQ ID NO: 164 og en let kædes CDR3-region ifølge SEQ ID NO: 172 og en tung kædes CDRl-region ifølge SEQ ID NO: 139, en tung kædes CDR2-region ifølge SEQ ID NO: 134 og en tung kædes CDR3-region ifølge SEQ ID NO:152 og en let kædes CDRl-region ifølge SEQ ID NO: 142, en let kædes CDR2-region ifølge SEQ ID NO: 143 og en let kædes CDR3-region ifølge SEQ ID NO: 144.
4. Nukleinsyremolekyle, der koder for et antistof eller et antigenbindende fragment deraf ifølge et hvilket som helst af kravene 1-3.
5. Antistof eller antigenbindende fragment deraf ifølge et hvilket som helst af kravene 1-3 og/eller et nukleinsyremolekyle ifølge krav 4 til anvendelse som et medikament.
6. Antistof eller antigenbindende fragment deraf ifølge krav 5 til anvendelse til profylaktisk og/eller terapeutisk behandling af influenzainfektion.
7. Farmaceutisk sammensætning, der omfatter et antistof eller et antigenbindende fragment deraf ifølge et hvilket som helst af kravene 1-3 og/eller et nukleinsyremolekyle ifølge krav 4 og et farmaceutisk acceptabelt excipiens.
DK12735516.2T 2011-07-14 2012-07-12 Humane bindingsmolekyler, der er i stand til at neutralisere influenza a-virus fra fylogenetisk gruppe 1 og fylogenetisk gruppe 2 og influenza b-virus DK2731967T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161572417P 2011-07-14 2011-07-14
EP11173953 2011-07-14
PCT/EP2012/063637 WO2013007770A1 (en) 2011-07-14 2012-07-12 Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses

Publications (1)

Publication Number Publication Date
DK2731967T3 true DK2731967T3 (da) 2017-01-16

Family

ID=47505543

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12735516.2T DK2731967T3 (da) 2011-07-14 2012-07-12 Humane bindingsmolekyler, der er i stand til at neutralisere influenza a-virus fra fylogenetisk gruppe 1 og fylogenetisk gruppe 2 og influenza b-virus

Country Status (17)

Country Link
US (2) US8961978B2 (da)
EP (1) EP2731967B1 (da)
JP (1) JP5683752B2 (da)
KR (1) KR101941724B1 (da)
CN (1) CN103906763B (da)
AU (1) AU2012282504B2 (da)
BR (1) BR112014000263B1 (da)
CA (1) CA2838999C (da)
DK (1) DK2731967T3 (da)
EA (1) EA027054B1 (da)
ES (1) ES2608321T3 (da)
HR (1) HRP20161740T1 (da)
IL (1) IL230222A (da)
IN (1) IN2014CN00953A (da)
MX (1) MX346206B (da)
MY (1) MY166282A (da)
WO (1) WO2013007770A1 (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103906763B (zh) 2011-07-14 2016-10-12 克鲁塞尔荷兰公司 能够中和系统发育群1和系统发育群2的a型流感病毒以及b型流感病毒的人结合分子
IN2014CN04742A (da) 2011-11-28 2015-09-18 Crucell Holland Bv
DK2793945T3 (da) 2011-12-05 2018-09-03 Trellis Bioscience Llc Nyttige antistoffer til passiv influenzaimmunisering
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US9649375B2 (en) 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
RU2701694C2 (ru) 2013-03-14 2019-09-30 Контрафект Корпорейшн Композиции и способы, основанные на нейтрализующих антителах, доставляемых интраназально, для улучшенной терапевтической эффективности
KR20140118682A (ko) * 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
EP3004142B1 (en) 2013-05-30 2020-09-30 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
RU2683498C2 (ru) 2013-10-02 2019-03-28 МЕДИММЬЮН, ЭлЭлСи Нейтрализующие антитела к вирусу гриппа а и пути их применения
RU2682049C2 (ru) * 2014-01-27 2019-03-14 Дженентек, Инк. Лечение вируса гриппа а h7n9
CN106795216B (zh) * 2014-02-04 2021-04-20 抗非特公司 可用于被动流感免疫的抗体及其组合物、组合和使用方法
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
CN105992772A (zh) * 2014-02-10 2016-10-05 Igm生命科学股份有限公司 IgA多特异性结合分子
CA2942820A1 (en) * 2014-03-27 2015-10-01 Genentech, Inc. Anti-influenza b virus hemagglutinin antibodies and methods of use
KR101628331B1 (ko) * 2014-03-28 2016-06-08 주식회사 녹십자엠에스 인플루엔자 a 바이러스 특이적 단클론 항체 및 이를 이용한 인플루엔자 감염 치료 및 진단 방법
BR112017000257A2 (pt) 2014-07-10 2017-10-31 Janssen Vaccines & Prevention Bv vacinas contra o vírus da gripe e usos das mesmas
BR112016030577A8 (pt) 2014-07-10 2021-07-20 Janssen Vaccines & Prevention Bv polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, composição e usos destes
RU2739952C2 (ru) * 2014-07-15 2020-12-30 МЕДИММЬЮН, ЭлЭлСи Нейтрализующие антитела к вирусу гриппа b и пути их применения
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
EP3253787B1 (en) 2015-02-05 2020-10-07 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza neuraminidase
MY186585A (en) * 2015-02-05 2021-07-28 Janssen Vaccines & Prevention Bv Binding molecules directed against influenza hemagglutinin and uses thereof
JP6960856B2 (ja) 2015-04-08 2021-11-05 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ヒト化インフルエンザモノクローナル抗体およびその使用方法
CA2985402A1 (en) 2015-05-11 2016-11-17 Janssen Vaccines & Prevention B.V. Influenza virus neutralizing peptidomimetic compounds
AU2016275909A1 (en) 2015-05-13 2017-11-09 The Trustees Of The University Of Pennsylvania AAV-mediated expression of anti-influenza antibodies and methods of use thereof
SI3303384T1 (sl) * 2015-06-01 2021-11-30 Medimmune Llc Nevtralizirajoče vezavne molekule proti-influenci in njihova uporaba
US10513553B2 (en) 2015-11-13 2019-12-24 Visterra, Inc. Compositions and methods for treating and preventing influenza
EP3402513A4 (en) * 2016-01-13 2019-10-23 Medlmmune, LLC METHOD OF TREATING A FLU
US10703803B2 (en) 2016-03-01 2020-07-07 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza B neuraminidase
WO2017192589A1 (en) * 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
WO2018038096A1 (ja) * 2016-08-23 2018-03-01 国立大学法人東京大学 モノクローナル抗体又はその抗原結合フラグメント及びその使用
KR20190071714A (ko) 2016-10-27 2019-06-24 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 중화 화합물
CA3051377A1 (en) 2017-01-27 2018-08-02 National Research Council Of Canada Hemagglutinin-specific antibodies and uses thereof
AU2018216954B2 (en) 2017-02-02 2022-04-14 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibition
WO2018141854A1 (en) 2017-02-02 2018-08-09 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibition
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
US11827906B2 (en) 2017-02-28 2023-11-28 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clade f vector and uses therefor
CA3052487A1 (en) 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Influenza vaccines based on aav vectors
SG11202006399VA (en) 2018-01-23 2020-08-28 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
EA202091563A1 (ru) 2018-01-26 2020-10-08 Регенерон Фармасьютикалз, Инк. Человеческие антитела к гемагглютинину вируса гриппа
AU2020248404A1 (en) 2019-03-25 2021-09-30 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2021043869A1 (en) 2019-09-05 2021-03-11 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
WO2021173965A1 (en) 2020-02-28 2021-09-02 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
US11175293B1 (en) 2021-01-04 2021-11-16 University Of Utah Research Foundation Rapid assay for detection of SARS-CoV-2 antibodies
WO2022166767A1 (zh) 2021-02-04 2022-08-11 四川海思科制药有限公司 Ha抑制剂化合物的盐及晶型
WO2024104947A2 (en) 2022-11-14 2024-05-23 Janssen Vaccines & Prevention B.V. Influenza b virus vaccines and uses thereof
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DE69718341T2 (de) 1996-10-08 2003-10-30 Bisys B V U Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül
EP1533380B1 (en) 1999-04-15 2009-11-04 Crucell Holland B.V. Recombinant protein production in a human cell comprising at least one E1 protein of adenovirus
WO2002103012A1 (en) 2001-06-15 2002-12-27 Crucell Holland B.V. Chimaeric phages
AU2007293662B2 (en) * 2006-09-07 2012-10-04 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
FR2921928B1 (fr) * 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
KR101732056B1 (ko) * 2008-07-25 2017-05-02 인스티튜트 포 리서치 인 바이오메드슨 중화 항-인플루엔자 ａ 바이러스 항체 및 이의 용도
EP2168987A1 (en) * 2008-09-22 2010-03-31 Mucosis B.V. Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain
CN102448986B (zh) 2009-05-11 2015-11-25 克鲁塞尔荷兰公司 能中和流感病毒h3n2的人结合分子及其应用
CN103906763B (zh) 2011-07-14 2016-10-12 克鲁塞尔荷兰公司 能够中和系统发育群1和系统发育群2的a型流感病毒以及b型流感病毒的人结合分子

Also Published As

Publication number Publication date
US8961978B2 (en) 2015-02-24
AU2012282504A1 (en) 2014-02-06
US20140120113A1 (en) 2014-05-01
CA2838999A1 (en) 2013-01-17
KR101941724B1 (ko) 2019-01-23
BR112014000263A2 (pt) 2017-02-14
EA027054B1 (ru) 2017-06-30
MY166282A (en) 2018-06-25
HRP20161740T1 (hr) 2017-02-10
MX2014000373A (es) 2014-03-31
JP5683752B2 (ja) 2015-03-11
MX346206B (es) 2017-03-09
AU2012282504B2 (en) 2017-07-20
US9593159B2 (en) 2017-03-14
WO2013007770A1 (en) 2013-01-17
NZ618530A (en) 2016-05-27
CN103906763B (zh) 2016-10-12
IL230222A (en) 2017-09-28
ES2608321T3 (es) 2017-04-07
EP2731967B1 (en) 2016-10-12
JP2014527403A (ja) 2014-10-16
US20150274811A1 (en) 2015-10-01
EA201490288A1 (ru) 2014-05-30
KR20140095017A (ko) 2014-07-31
CN103906763A (zh) 2014-07-02
IN2014CN00953A (da) 2015-04-10
EP2731967A1 (en) 2014-05-21
CA2838999C (en) 2021-02-16
BR112014000263B1 (pt) 2022-01-18

Similar Documents

Publication Publication Date Title
DK2731967T3 (da) Humane bindingsmolekyler, der er i stand til at neutralisere influenza a-virus fra fylogenetisk gruppe 1 og fylogenetisk gruppe 2 og influenza b-virus
AU2010247530B2 (en) Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
KR101485197B1 (ko) 인플루엔자 바이러스 ｈ5ｎ1을 중화시킬 수 있는 인간 결합분자 및 그것의 용도
CN101541832B (zh) 能中和流感病毒h5n1的人结合分子及其应用
AU2006290736A1 (en) Method for preparing immunoglobulin libraries
DK2455399T3 (da) Humane bindingsmolekyler, der er i stand til at neutralisere influenzavirus h5n1, og anvendelser deraf
NZ618530B2 (en) Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses